Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan.

Matteo BargagliNasser A DhayatManuel AndereggMariam SemmoUyen Huynh-DoBruno VogtPietro Manuel Ferraro Daniel G Fuster

Published in: Clinical journal of the American Society of Nephrology : CJASN (2020)

Tolvaptan treatment is associated with a significantly improved urinary lithogenic risk profile in patients with ADPKD.

Keyphrases